{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:10:46Z","timestamp":1767834646931,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["RSPD2025R980"],"award-info":[{"award-number":["RSPD2025R980"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Central Council for Research in Unani Medicine","award":["Grant No. 3-69\/2020- CCRUM\/Tech"],"award-info":[{"award-number":["Grant No. 3-69\/2020- CCRUM\/Tech"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10822-025-00606-3","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T23:42:08Z","timestamp":1749685328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Structure-guided discovery of microtubule affinity-regulating kinase 4 inhibitory potential of Harmane: towards therapeutic targeting of Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"39","author":[{"given":"Afzal","family":"Hussain","sequence":"first","affiliation":[]},{"given":"Md. Nayab","family":"Sulaimani","sequence":"additional","affiliation":[]},{"given":"Shumayila","family":"Khan","sequence":"additional","affiliation":[]},{"given":"Saleha","family":"Anwar","sequence":"additional","affiliation":[]},{"given":"Mohammed F.","family":"Hawwal","sequence":"additional","affiliation":[]},{"given":"Mohamed F.","family":"Alajmi","sequence":"additional","affiliation":[]},{"given":"Dharmendra Kumar","family":"Yadav","sequence":"additional","affiliation":[]},{"given":"Md. Imtaiyaz","family":"Hassan","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"606_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.arr.2024.102476","volume":"101","author":"S Prabha","year":"2024","unstructured":"Prabha S, Sajad M, Hasan GM, Islam A, Imtaiyaz Hassan M et al (2024) Recent advancement in Understanding of Alzheimer\u2019s disease: risk factors, subtypes, and drug targets and potential therapeutics. Ageing Res Rev 101:102476.","journal-title":"Ageing Res Rev"},{"key":"606_CR2","doi-asserted-by":"publisher","first-page":"101924","DOI":"10.1016\/j.arr.2023.101924","volume":"87","author":"S Khan","year":"2023","unstructured":"Khan S, Hassan MI, Shahid M, Islam A (2023) Nature\u2019s toolbox against Tau aggregation: an updated review of current research. Ageing Res Rev 87:101924","journal-title":"Ageing Res Rev"},{"key":"606_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.arr.2023.102113","volume":"92","author":"T Khan","year":"2023","unstructured":"Khan T, Waseem R, Shahid M, Ansari J, Ahanger IA et al (2023) Recent advancement in therapeutic strategies for Alzheimer\u2019s disease: insights from clinical trials. Ageing Res Rev 92:102113.","journal-title":"Ageing Res Rev"},{"key":"606_CR4","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.3390\/ijms25105169","volume":"25","author":"J Li","year":"2024","unstructured":"Li J, Haj Ebrahimi A, Ali AB (2024) Advances in therapeutics to alleviate cognitive decline and neuropsychiatric symptoms of Alzheimer\u2019s disease. Int J Mol Sci 25:5169","journal-title":"Int J Mol Sci"},{"key":"606_CR5","first-page":"39","volume":"23","author":"AK Singh","year":"2024","unstructured":"Singh AK, Malviya R, Prakash A, Verma S (2024) Neuropsychiatric manifestations in Alzheimer\u2019s disease patients: genetics and treatment options. CNS & neurological Disorders-Drug targets (Formerly current drug targets-CNS &. Neurol Disorders) 23:39\u201354","journal-title":"Neurol Disorders)"},{"key":"606_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, De Strooper B, Frisoni GB et al (2016) Alzheimer\u2019s disease. Lancet 388:505\u2013517","journal-title":"Lancet"},{"key":"606_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G et al (2021) Alzheimer\u2019s disease. Lancet 397:1577\u20131590","journal-title":"Lancet"},{"key":"606_CR8","first-page":"7","volume":"64","author":"GL Wenk","year":"2003","unstructured":"Wenk GL (2003) Neuropathologic changes in Alzheimer\u2019s disease. J Clin Psychiatry 64:7\u201310","journal-title":"J Clin Psychiatry"},{"key":"606_CR9","doi-asserted-by":"crossref","unstructured":"Prabha S, Choudhury A, Islam A, Thakur SC, Hassan MI (2025) Understanding of Alzheimer\u2019s Disease Pathophysiology for Therapeutic Implications of Natural Products as Neuroprotective Agents. Ageing Res Rev 105:102680","DOI":"10.1016\/j.arr.2025.102680"},{"key":"606_CR10","doi-asserted-by":"crossref","unstructured":"Yu Y, Yu S, Battaglia G, Tian X (2024) Amyloid-\u03b2 in Alzheimer\u2019s disease: Structure, toxicity, distribution, treatment, and prospects. Ibrain 10:266-289.","DOI":"10.1002\/ibra.12155"},{"key":"606_CR11","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jcomdis.2010.04.011","volume":"43","author":"J Reilly","year":"2010","unstructured":"Reilly J, Rodriguez AD, Lamy M, Neils-Strunjas J (2010) Cognition, Language, and clinical pathological features of non-Alzheimer\u2019s dementias: an overview. J Commun Disord 43:438\u2013452","journal-title":"J Commun Disord"},{"key":"606_CR12","doi-asserted-by":"publisher","first-page":"12841","DOI":"10.3390\/ijms232112841","volume":"23","author":"P Rawat","year":"2022","unstructured":"Rawat P, Sehar U, Bisht J, Selman A, Culberson J et al (2022) Phosphorylated Tau in Alzheimer\u2019s disease and other Tauopathies. Int J Mol Sci 23:12841","journal-title":"Int J Mol Sci"},{"key":"606_CR13","doi-asserted-by":"crossref","unstructured":"Singh A, Ansari VA, Mahmood T, Hasan SM, Wasim R et al (2024) Targeting abnormal Tau phosphorylation for Alzheimer\u2019s therapeutics. Hormone and Metabolic Research;56:482-488","DOI":"10.1055\/a-2238-1384"},{"key":"606_CR14","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.2174\/0929867329666220301115124","volume":"29","author":"D Catarzi","year":"2022","unstructured":"Catarzi D, Varano F, Vigiani E, Lambertucci C, Spinaci A et al (2022) Casein kinase 1\u03b4 inhibitors as promising therapeutic agents for neurodegenerative disorders. Curr Med Chem 29:4698\u20134737","journal-title":"Curr Med Chem"},{"key":"606_CR15","doi-asserted-by":"publisher","first-page":"916063","DOI":"10.3389\/fmolb.2022.916063","volume":"9","author":"A Baier","year":"2022","unstructured":"Baier A, Szyszka R (2022) CK2 and protein kinases of the CK1 superfamily as targets for neurodegenerative disorders. Front Mol Biosci 9:916063","journal-title":"Front Mol Biosci"},{"key":"606_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/med.21928","volume":"43","author":"AK ElHady","year":"2023","unstructured":"ElHady AK, El-Gamil DS, Abadi AH, Abdel\u2010Halim M, Engel M (2023) An overview of cdc2\u2010like kinase 1 (Clk1) inhibitors and their therapeutic indications. Med Res Rev 43:343\u2013398","journal-title":"Med Res Rev"},{"key":"606_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/0115672050301407240408033046","volume":"21","author":"S Kalyaanamoorthy","year":"2024","unstructured":"Kalyaanamoorthy S, Opare SK, Xu X, Ganesan A, Rao PP (2024) Post-Translational modifications in Tau and their roles in Alzheimer\u2019s pathology. Curr Alzheimer Res 21:24\u201349","journal-title":"Curr Alzheimer Res"},{"key":"606_CR18","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/biof.1930","volume":"49","author":"G Montalto","year":"2023","unstructured":"Montalto G, Ricciarelli R (2023) Tau, Tau kinases, and Tauopathies: an updated overview. BioFactors 49:502\u2013511","journal-title":"BioFactors"},{"key":"606_CR19","doi-asserted-by":"crossref","unstructured":"Hekmat A, Saboury AA (2022) Protein kinase inhibitors and cancer targeted therapy. Protein Kinase Inhibitors: Elsevier, pp 23\u201370","DOI":"10.1016\/B978-0-323-91287-7.00022-3"},{"key":"606_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2051-5960-2-22","volume":"2","author":"H Lund","year":"2014","unstructured":"Lund H, Gustafsson E, Svensson A, Nilsson M, Berg M et al (2014) MARK4 and MARK3 associate with early Tau phosphorylation in Alzheimer\u2019s disease granulovacuolar degeneration bodies. Acta Neuropathol Commun 2:1\u201315","journal-title":"Acta Neuropathol Commun"},{"key":"606_CR21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s12017-013-8232-3","volume":"15","author":"GJ Gu","year":"2013","unstructured":"Gu GJ, Lund H, Wu D, Blokzijl A, Classon C et al (2013) Role of individual MARK isoforms in phosphorylation of Tau at Ser262 in Alzheimer\u2019s disease. Neuromol Med 15:458\u2013469","journal-title":"Neuromol Med"},{"key":"606_CR22","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/s41380-023-02113-z","volume":"28","author":"N Basheer","year":"2023","unstructured":"Basheer N, Smolek T, Hassan I, Liu F, Iqbal K et al (2023) Does modulation of Tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer\u2019s disease? From preclinical studies to the clinical trials. Mol Psychiatry 28:2197\u20132214","journal-title":"Mol Psychiatry"},{"key":"606_CR23","first-page":"100076","volume":"6","author":"M Voura","year":"2022","unstructured":"Voura M, Anwar S, Thysiadis S, \u039ahan P, Dalezis P et al (2022) Synthesis and biological activity of bisindole derivatives as novel MARK4 inhibitors. Eur J Med Chem Rep 6:100076","journal-title":"Eur J Med Chem Rep"},{"key":"606_CR24","doi-asserted-by":"publisher","first-page":"132425","DOI":"10.1016\/j.ijbiomac.2024.132425","volume":"271","author":"S Anwar","year":"2024","unstructured":"Anwar S, Hassan MI, Parvez S (2024) Ropinirole reverses the effects of neuroinflammation, and cellular demise by downregulating the MARK4-NF\u03ba\u03b2 signaling system in Alzheimer\u2019s disease. Int J Biol Macromol 271:132425","journal-title":"Int J Biol Macromol"},{"key":"606_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2015.01.057","volume":"590","author":"HA Ghazaleh","year":"2015","unstructured":"Ghazaleh HA, Lalies MD, Nutt DJ, Hudson AL (2015) Harmane: an atypical neurotransmitter? Neurosci Lett 590:1\u20135","journal-title":"Neurosci Lett"},{"key":"606_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejphar.2013.12.038","volume":"724","author":"A Daoud","year":"2014","unstructured":"Daoud A, Song J, Xiao F, Shang J (2014) B-9-3, a novel \u03b2-carboline derivative exhibits anti-cancer activity via induction of apoptosis and Inhibition of cell migration in vitro. Eur J Pharmacol 724:219\u2013230","journal-title":"Eur J Pharmacol"},{"key":"606_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1586\/ern.11.1","volume":"11","author":"W Polanski","year":"2011","unstructured":"Polanski W, Reichmann H, Gille G (2011) Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-\u03b2-carboline: a new anti-Parkinson drug? Expert Rev Neurother 11:845\u2013860","journal-title":"Expert Rev Neurother"},{"key":"606_CR28","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1021\/mp400531n","volume":"10","author":"C Domonkos","year":"2013","unstructured":"Domonkos C, Fitos I, Visy Jl, Zsila F (2013) Fatty acid modulated human serum albumin binding of the \u03b2-carboline alkaloids Norharmane and Harmane. Mol Pharm 10:4706\u20134716","journal-title":"Mol Pharm"},{"key":"606_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1196\/annals.1304.020","volume":"1009","author":"NJ Anderson","year":"2003","unstructured":"Anderson NJ, Robinson EJ, Husbands SM, Delagrange P, Nutt DJ et al (2003) Characterization of [3H] Harmane binding to rat whole brain membranes. Ann N Y Acad Sci 1009:175\u2013179","journal-title":"Ann N Y Acad Sci"},{"key":"606_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.exppara.2004.04.002","volume":"106","author":"C Di Giorgio","year":"2004","unstructured":"Di Giorgio C, Delmas F, Ollivier E, Elias R, Balansard G et al (2004) In vitro activity of the \u03b2-carboline alkaloids Harmane, Harmine, and harmaline toward parasites of the species leishmania infantum. Exp Parasitol 106:67\u201374","journal-title":"Exp Parasitol"},{"key":"606_CR31","doi-asserted-by":"crossref","unstructured":"Stanzione F, Giangreco I, Cole J (2021) Chapter four\u2014use of molecular Docking computational tools in drug discovery. Prog Med Chem: 273\u2013343","DOI":"10.1016\/bs.pmch.2021.01.004"},{"key":"606_CR32","doi-asserted-by":"publisher","first-page":"e3104","DOI":"10.1002\/jmr.3104","volume":"38","author":"AI Uba","year":"2025","unstructured":"Uba AI (2025) Computer-Aided design of VEGFR\u20102 inhibitors as anticancer agents: A review. J Mol Recognit 38:e3104","journal-title":"J Mol Recognit"},{"key":"606_CR33","doi-asserted-by":"publisher","first-page":"127036","DOI":"10.1016\/j.ijbiomac.2023.127036","volume":"253","author":"I Shakeel","year":"2023","unstructured":"Shakeel I, Khan S, Roy S, Sherwani F, Ahmad SF et al (2023) Investigating potential of cholic acid, syringic acid, and mangiferin as cancer therapeutics through sphingosine kinase 1 Inhibition. Int J Biol Macromol 253:127036","journal-title":"Int J Biol Macromol"},{"key":"606_CR34","doi-asserted-by":"publisher","first-page":"129314","DOI":"10.1016\/j.ijbiomac.2024.129314","volume":"259","author":"DS Jairajpuri","year":"2024","unstructured":"Jairajpuri DS, Khan S, Anwar S, Hussain A, Alajmi MF et al (2024) Investigating the role of thymol as a promising inhibitor of pyruvate dehydrogenase kinase 3 for targeted cancer therapy. Int J Biol Macromol 259:129314","journal-title":"Int J Biol Macromol"},{"key":"606_CR35","doi-asserted-by":"crossref","unstructured":"Taiyab A, Mohammad T, Sulaimani MN, Anjum F, Azum N et al (2025) Structure-guided identification of potential MTH1 inhibitors from natural compounds: toward therapeutic targeting of oxidative DNA damage in cancer. Chemical Papers 79: 1477\u20131492,","DOI":"10.1007\/s11696-024-03869-6"},{"key":"606_CR36","unstructured":"Inc. AB (2025) IC50 Calculator"},{"key":"606_CR37","doi-asserted-by":"crossref","unstructured":"Morris GM, Lim-Wilby M (2008) Molecular docking. Molecular modeling of proteins Methods Mol Biol 443:365\u201382.","DOI":"10.1007\/978-1-59745-177-2_19"},{"key":"606_CR38","doi-asserted-by":"publisher","first-page":"134824","DOI":"10.1016\/j.foodchem.2022.134824","volume":"405","author":"X Hu","year":"2023","unstructured":"Hu X, Zeng Z, Zhang J, Wu D, Li H et al (2023) Molecular dynamics simulation of the interaction of food proteins with small molecules. Food Chem 405:134824","journal-title":"Food Chem"},{"key":"606_CR39","doi-asserted-by":"crossref","unstructured":"Habib I, Sulaimani MN, Hussain A, Gulzar M, Mohammad T et al (2024) Identification of potential bioactive phytochemicals for the Inhibition of Platelet-Derived growth factor receptor \u0392. An integrated docking and MD simulation approach","DOI":"10.21203\/rs.3.rs-4224673\/v1"},{"key":"606_CR40","doi-asserted-by":"publisher","first-page":"10558","DOI":"10.1080\/07391102.2022.2154849","volume":"41","author":"MI Hassan","year":"2023","unstructured":"Hassan MI, Anjum D, Mohammad T, Alam M, Khan MS et al (2023) Integrated virtual screening and MD simulation study to discover potential inhibitors of Lyn-kinase: targeting cancer therapy. J Biomol Struct Dynamics 41:10558\u201310568","journal-title":"J Biomol Struct Dynamics"},{"key":"606_CR41","doi-asserted-by":"crossref","unstructured":"Anwar S, Khan S, Hussain A, Alajmi MF, Shamsi A et al (2024) Investigating pyruvate dehydrogenase kinase 3 inhibitory potential of myricetin using integrated computational and spectroscopic approaches. ACS omega 9: 29633\u201329643.","DOI":"10.1021\/acsomega.4c03001"},{"key":"606_CR42","doi-asserted-by":"publisher","first-page":"130090","DOI":"10.1016\/j.ijbiomac.2024.130090","volume":"262","author":"S Anwar","year":"2024","unstructured":"Anwar S, Choudhury A, Hussain A, AlAjmi MF, Hassan MI et al (2024) Harnessing memantine in Alzheimer\u2019s disease therapy through Inhibition of microtubule affinity-regulating kinase: mechanistic insights. Int J Biol Macromol 262:130090","journal-title":"Int J Biol Macromol"},{"key":"606_CR43","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/med.21562","volume":"39","author":"G Caron","year":"2019","unstructured":"Caron G, Kihlberg J, Ermondi G (2019) Intramolecular hydrogen bonding: an opportunity for improved design in medicinal chemistry. Med Res Rev 39:1707\u20131729","journal-title":"Med Res Rev"},{"key":"606_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jmb.2010.09.034","volume":"404","author":"RB Cooley","year":"2010","unstructured":"Cooley RB, Arp DJ, Karplus PA (2010) Evolutionary origin of a secondary structure: \u03c0-helices as cryptic but widespread insertional variations of \u03b1-helices that enhance protein functionality. J Mol Biol 404:232\u2013246","journal-title":"J Mol Biol"},{"key":"606_CR45","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1111\/febs.13507","volume":"282","author":"P Kumar","year":"2015","unstructured":"Kumar P, Bansal M (2015) Dissecting \u03c0-helices: sequence, structure and function. FEBS J 282:4415\u20134432","journal-title":"FEBS J"},{"key":"606_CR46","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/jpm12071083","volume":"12","author":"M Adnan","year":"2022","unstructured":"Adnan M, Jairajpuri DS, Chaddha M, Khan MS, Yadav DK et al (2022) Discovering Tuberosin and villosol as potent and selective inhibitors of AKT1 for therapeutic targeting of oral squamous cell carcinoma. J Personalized Med 12:1083","journal-title":"J Personalized Med"},{"key":"606_CR47","first-page":"298","volume":"5","author":"A Kitao","year":"2022","unstructured":"Kitao A (2022) Principal component analysis and related methods for investigating the dynamics of biological macromolecules. J 5:298\u2013317","journal-title":"J"},{"key":"606_CR48","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jmgm.2009.01.006","volume":"27","author":"E Papaleo","year":"2009","unstructured":"Papaleo E, Mereghetti P, Fantucci P, Grandori R, De Gioia L (2009) Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: the myoglobin case. J Mol Graph Model 27:889\u2013899","journal-title":"J Mol Graph Model"},{"key":"606_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/156802610790232279","volume":"10","author":"RE Amaro","year":"2010","unstructured":"Amaro RE, Li WW (2010) Emerging methods for ensemble-based virtual screening. Curr Top Med Chem 10:3\u201313","journal-title":"Curr Top Med Chem"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00606-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00606-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00606-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:56:07Z","timestamp":1762451767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00606-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00606-3","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have given final approval of the version and agreed with the publication of this study here. Declaration of AI Assistance: The authors acknowledge the use of AI tools for language refinement and improvement during the preparation of this manuscript. Specifically, AI assistance was utilized to enhance the clarity, grammar, and overall readability of the text. All content was carefully reviewed and verified by the authors to ensure its accuracy and integrity.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}